MaxCyte, Inc. (MXCT)

Market Cap	90.32M -68.8%
Revenue (ttm)	33.03M -14.5%
Net Income	-44.63M
EPS	-0.42
Shares Out	106.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	563,998
Open	0.8999
Previous Close	0.8814
Day's Range	0.8232 - 0.8999
52-Week Range	0.6434 - 2.9550
Beta	1.45
Analysts	Buy
Price Target	5.50 (+550.73%)
Earnings Date	May 6, 2026

About MXCT

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engi...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 91
• Stock Exchange: NASDAQ
• Ticker Symbol: MXCT
• Website: https://www.maxcyte.com

Financial Performance

In 2025, MaxCyte's revenue was $33.03 million, a decrease of -14.50% compared to the previous year's $38.63 million. Losses were -$44.63 million, 8.71% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for MXCT stock is "Buy." The 12-month stock price target is $5.5, which is an increase of 550.73% from the latest price.

Price Target

$5.5

(550.73% upside)

Analyst Consensus: Buy